图

上周五上午听的是Longevity Biotech Fellowship（LBF）的运营负责人Eric Magro的分享。这个成立约三年的非营利组织专注一件事：把“解决衰老”当成一个值得立项、拨款、招人的工程问题来做。

Eric开场放了一张死亡率曲线。年轻时，我们的死亡概率几乎贴地飞行，到了某个年龄后会突然指数级拉升。衰老，是全球大多数人的死因本质，但目前没有一个国家或大型机构在系统性地拆解这个问题。LBF的路线图就是想补上这个“战略空白”。

Last Friday morning I sat in on a session by Eric, Head of Operations from Longevity Biotech Fellowship (LBF). Founded roughly three years ago, this nonprofit focuses on one thing: treating "solving aging" as an engineering problem worthy of formal project launch, funding, and hiring.

Eric opened with a mortality curve. When we're young, the probability of death hovers near zero; after a certain age, it spikes exponentially. Aging is essentially the leading cause of death worldwide, yet no country or major institution is systematically dismantling the problem. LBF's roadmap aims to fill this strategic void.

[ LBF把解题思路系统性地拆成三条（难度和资金需求依次递减）]

生物工程（Bioengineering）：彻底理解衰老生物学并干预。Eric认为这是最难、最花钱、最遥远的方向，因为人类至今没有公认的衰老理论框架，连因果通路都没完全摸清。

生物停滞（Biostasis）：在衰老被解决前，把人“暂停”。主要是低温保存（cryonics），也包括其他尚未成熟的技术。Eric强调这更像工程问题而非基础科学问题，且目前全球从业者极少、资金严重不足。

替换（Replacement）： 哪里坏了换哪里，从细胞、组织、器官到全身替换。LBF认为这条路径的成本和时间预估远低于生物工程，因此他们最为之兴奋。

[LBF breaks the solution into three paths, ranked by difficulty and capital needs]

Bioengineering — fully understanding and intervening in aging biology. Eric considers this the hardest, most expensive, and most distant route. Humanity still lacks a consensus theoretical framework for aging; we haven't even fully mapped the causal pathways.

Biostasis — putting people "on pause" until aging is solved. Primarily cryonics, plus other immature tech. Eric stresses this is more engineering than basic science, but global practitioners are scarce and funding is severely lacking.

Replacement — swapping out whatever breaks, from cells to tissues to organs to whole bodies. LBF estimates this path demands far less cost and time than bioengineering, which is why they're most excited about it.

[一些技术节点性事件